Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Banco de datos
Tipo de estudio
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Neurol Res ; 40(7): 523-531, 2018 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-29726751

RESUMEN

INTRODUCTION: Studies have shown that hydrogen sulfide (H2S), a gaseous neurotransmitter, has neuroprotective effect. Here, we evaluated the neuroprotective activity of H2S in acute 6-hydroxydopamine (6-OHDA) animal model of Parkinson's disease (PD). METHODS: 6-OHDA was injected through stereotaxic surgery into medial forebrain bundle (MFB) of the right hemisphere to induce severe and fast degeneration in dopaminergic neurons of substantia nigra (SN). NaHS, as donor of H2S, was daily injected at doses of 3 and 5.6 mg/kg for seven days starting a few hours before the surgery. A series of behavioral tests were carried out and then, remaining tyrosine hydroxylase (TH)-positive neurons in substantia nigra pars compacta (SNc) was determined using immunohistfluresance staining. Striatal dopamine level and oxidative stress markers were also measured in the brain homogenates using immunosorbent assay kits. RESULTS: NaHS attenuated apomorphine-induced rotational activity, decreased bias swings in elevated body swing test and increased falling time in rotarod test. Our histological and biochemical data demonstrated that NaHS treatment increases the survival of TH-positive neurons in SNc and also reduces the decreasing effect of 6-OHDA on striatal dopamine level. NaHS also reduced 6-OHDA-induced malondialdehyde overproduction but had no effect on the superoxide dismutase and glutathione peroxidase activity. CONCLUSION: Our results show that H2S produces significant antiparkinsonism and neuroprotective effects against 6-OHDA neurotoxicity. Since injection of 6-OHDA into MFB produces severe lesion in SN dopaminergic neurons similar to this lesion in the onset of PD in human being, our data recommend H2S as potential therapeutic target for treatment of this disease.


Asunto(s)
Dopamina/metabolismo , Sulfuro de Hidrógeno/uso terapéutico , Fármacos Neuroprotectores/uso terapéutico , Enfermedad de Parkinson/tratamiento farmacológico , Enfermedad de Parkinson/metabolismo , Enfermedad de Parkinson/patología , Análisis de Varianza , Animales , Apomorfina/farmacología , Cuerpo Estriado/efectos de los fármacos , Cuerpo Estriado/metabolismo , Modelos Animales de Enfermedad , Agonistas de Dopamina/farmacología , Relación Dosis-Respuesta a Droga , Glutatión Peroxidasa/metabolismo , Masculino , Malondialdehído/metabolismo , Actividad Motora/efectos de los fármacos , Oxidopamina/toxicidad , Enfermedad de Parkinson/etiología , Equilibrio Postural/efectos de los fármacos , Ratas , Ratas Wistar , Prueba de Desempeño de Rotación con Aceleración Constante , Superóxido Dismutasa/metabolismo , Simpaticolíticos/toxicidad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA